Anselamimab - CISMeF

Preferred Label : Anselamimab;

NCIt synonyms : mAb-11-1F4; Chimeric Amyloid-reactive Monoclonal Antibody CAEL-101; c11-1F4 mAb; Chimeric Fibril-reactive Monoclonal Antibody CAEL-101;

NCIt definition : A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, anselamimab targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.;

UNII : TL94QQ5RTW;

CAS number : 2414866-63-8;

Molecule name : 11-1F4; CAEL 101; CAEL-101;

NCI Metathesaurus CUI : CL474109;

Details

Origin ID

C117241;

UMLS CUI

C5667143;

Currated CISMeF NLP mapping
- Anselamimab [SMS substance]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients